Dr. Eduardo E. Chang
Pulmonology (Pulmonary Disease Physician)
3115 College Park Dr Ste 110
The Woodlands, TX 77384
Who else practices at this address →
Montgomery County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 31
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 367
Licensed in California since 1999, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
LA license MD.022572 · CA license A67939 (first issued 1999; current) · TX license L0073 (first issued 2000; active) -
Allergy & Immunology (Internal Medicine) Physician
CA license A67939 (first issued 1999; current) -
Critical Care Medicine (Internal Medicine) Physician
CA license A67939 (first issued 1999; current) · IN license 01081155A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Union Hospital Inc Terre Haute, IN
- Sullivan County Community Hospital Sullivan, IN
Medical groups
- Vituity - Indiana Critical Care PC (7 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 367
- Services billed
- 1,020
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 821 | 342 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 135 | 93 |
| Critical care, each additional 30 minutes | 21 | 17 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 19 | 19 |
| Ultrasonic guidance for blood vessel access | 16 | 16 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $19.90 in total to this clinician.
| Merck Sharp & Dohme LLC | $19.90 |
|---|
| Food and Beverage | $19.90 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $166,426 in research payments for these studies, mostly to the institutions running them.
- A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment
AstraZeneca UK Limited - A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis
Sanofi US Services Inc. · Completed · NCT06280391 - A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulm…
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.